Holly Lofton, MD
Obesity Medicine · New York, NYNPI 1104010511
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $443,071 of the $637,561 with a category attached, or 69.5%. Novo Nordisk accounts for 64.5% of it on its own, with 19 other manufacturers making up the rest.
Across 923 payments — averaging $690.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$411K
- Lilly USA, LLC$182K
- Eli Lilly$28K
- Currax Pharmaceuticals LLC$7K
- AbbVie$2K
- Intra-sana Laboratories$2K
- plus $4K from 14 others
Across 420 payments — averaging $6187.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.2M
- Novo Nordisk$1M
- Novo Nordisk AS$283K
- Boehringer Ingelheim$28K
- Boehringer Ingelheim France S.a.s.$4K
- Amgen$652
What the payments were for
- Consulting fees$91,98814%
- Speaking & faculty fees$443,07169%
- Travel & lodging$77,87112%
- Food & beverage$24,4384%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 477 | $411,141 |
| Lilly USA, LLC | 248 | $182,477 |
| Eli Lilly | 106 | $28,227 |
| Currax Pharmaceuticals LLC | 24 | $7,498 |
| AbbVie(2 entities) | 2 | $2,275 |
| Intra-sana Laboratories | 7 | $1,999 |
| Madrigal Pharmaceuticals | 5 | $1,885 |
| W. L. Gore & Associates, Inc. | 5 | $361 |
| Johnson & Johnson | 5 | $348 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $293 |
| Boehringer Ingelheim | 9 | $273 |
| Endo Pharmaceuticals Inc. | 4 | $223 |
| Medtronic | 1 | $179 |
| BD | 3 | $103 |
| Eisai Inc. | 3 | $70 |
| Corcept Therapeutics | 3 | $65 |
| Perspectum Diagnostics Ltd | 1 | $53 |
| Shire North American Group Inc | 2 | $41 |
| Nalpropion Pharmaceuticals LLC | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$191,198
- Wegovy$163,176
- ZEPBOUND$158,885
- CONTRAVE$7,259
- IMBRUVICA$2,250
- Reltone 200 Mg$1,942
- GLYCATE$1,942
- Reltone 400 Mg$1,942
- REZDIFFRA$1,885
- Ozempic$1,860
- MOUNJARO$354
- SEAMGUARD$290
- ECHELON FLEX Stapler$238
- NASCOBAL$157
- RYBELSUS$125
How this compares
Too few obesity medicine providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 160 | $199,397 |
| MounjaroTirzepatide | 143 | $175,033 |
| OzempicSemaglutide | 123 | $161,897 |
| WegovySemaglutide | 50 | $70,229 |
| TrulicityDulaglutide | 18 | $17,886 |
| Naltrexone Hcl | 51 | $1,651 |
| Metformin Hcl ErMetformin Hcl | 98 | $1,039 |
| Ondansetron OdtOndansetron | 31 | $295 |
| Topiramate | 29 | $293 |
| Levothyroxine Sodium | 11 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $411,141 | $232,126173 claims |
| Boehringer IngelheimJardiance | $273 | $199,397160 claims |
| Lilly USA, LLCMounjaro, Trulicity | $182,477 | $192,919161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other obesity medicine in New York
- Sarah SchmitzNew York$3K
- Duane FredericksNew York$3K
- Anelise EngelNew York$750
- Ana Aida CaballesNew York$35
- Terry VuongSyosset$9K
- Jessica WitteOlean$7K
- Carol SantoroAlbany$1K
- Carl RuoffRoslyn Heights$348
- Thomas DoboszBuffalo$201
- Maysaa HameedRochester$187
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.